Sutro Biopharma (STRO) Gains from Investment Securities (2016 - 2025)

Sutro Biopharma has disclosed Gains from Investment Securities across 10 years of filings, most recently posting -$190000.0 for Q4 2025.

• Gains from Investment Securities for Q4 2025 came in at -$190000.0, up 84.81% year-over-year; the trailing twelve-month figure through Dec 2025 was -$2.1 million (down 9.94% YoY), and the FY2025 annual result was $359725.0, down 58.51% from the prior year.
• Gains from Investment Securities came in at -$190000.0 for Q4 2025 at Sutro Biopharma, down from $7.8 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $7.8 million in Q3 2025 to a low of -$1.3 million in Q4 2024.
• The 5-year median for Gains from Investment Securities is $14271.5 (2024), against an average of $443456.1.
• Across the five-year window, Gains from Investment Securities plunged 98.33% in 2021 and soared 38772.02% in 2025, its largest moves.
• Sutro Biopharma's Gains from Investment Securities stood at $30143.0 in 2021, then slumped by 74.77% to $7606.0 in 2022, then slumped by 14720.04% to -$1.1 million in 2023, then declined by 12.5% to -$1.3 million in 2024, then surged by 84.81% to -$190000.0 in 2025.
• The last three Gains from Investment Securities figures came in at -$190000.0 (Q4 2025), $7.8 million (Q3 2025), and $62739.0 (Q2 2025), per Business Quant data.